Advertisement
TAK Novinky na Forexu
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis
Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews
|
Před 487 dny
Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA
Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).
RTTNews
|
Před 541 dny
Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia
Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.
RTTNews
|
Před 627 dny
Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease
Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).
RTTNews
|
Před 639 dny
Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis
Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Monday positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.
RTTNews
|
Před 641 dny
